Cooper Companies (COO) Projected to Post Earnings on Thursday

Cooper Companies (NASDAQ:COO) is expected to announce its Q1 2026 results after the market closes on Thursday, March 5th. Analysts expect the company to announce earnings of $1.03 per share and revenue of $1.0237 billion for the quarter. Cooper Companies has set its FY 2026 guidance at 4.450-4.600 EPS and its Q1 2026 guidance at 1.020-1.040 EPS. Parties can find conference call details on the company’s upcoming Q1 2026 earning report page for the latest details on the call scheduled for Thursday, March 5, 2026 at 5:00 PM ET.

Cooper Companies (NASDAQ:COO) last issued its quarterly earnings results on Thursday, December 4th. The medical device company reported $1.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.11 by $0.04. Cooper Companies had a return on equity of 10.02% and a net margin of 9.16%.The firm had revenue of $1.07 billion during the quarter, compared to analyst estimates of $1.06 billion. During the same period last year, the company earned $1.04 EPS. Cooper Companies’s quarterly revenue was up 4.6% compared to the same quarter last year. On average, analysts expect Cooper Companies to post $4 EPS for the current fiscal year and $4 EPS for the next fiscal year.

Cooper Companies Price Performance

COO opened at $83.47 on Thursday. The business has a fifty day moving average of $82.22 and a 200 day moving average of $75.55. The stock has a market cap of $16.36 billion, a P/E ratio of 44.40, a PEG ratio of 2.39 and a beta of 1.03. The company has a quick ratio of 1.13, a current ratio of 1.89 and a debt-to-equity ratio of 0.30. Cooper Companies has a 52-week low of $61.78 and a 52-week high of $92.84.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on COO shares. Robert W. Baird upped their price target on shares of Cooper Companies from $85.00 to $98.00 and gave the stock an “outperform” rating in a report on Friday, December 5th. Mizuho set a $100.00 target price on shares of Cooper Companies and gave the stock an “outperform” rating in a research note on Friday, December 5th. Morgan Stanley raised their target price on shares of Cooper Companies from $76.00 to $83.00 and gave the stock an “equal weight” rating in a research report on Monday, December 8th. Piper Sandler reaffirmed an “overweight” rating and set a $94.00 price target (up from $83.00) on shares of Cooper Companies in a research note on Friday, December 5th. Finally, Citigroup reissued a “neutral” rating and issued a $88.00 price objective (up from $72.00) on shares of Cooper Companies in a research note on Monday, December 8th. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, six have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Cooper Companies currently has a consensus rating of “Moderate Buy” and a consensus price target of $90.77.

Insiders Place Their Bets

In other Cooper Companies news, CEO Albert G. White III bought 10,000 shares of the firm’s stock in a transaction that occurred on Tuesday, December 16th. The stock was bought at an average cost of $80.80 per share, for a total transaction of $808,000.00. Following the completion of the transaction, the chief executive officer directly owned 236,151 shares of the company’s stock, valued at approximately $19,081,000.80. This trade represents a 4.42% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Cynthia L. Lucchese purchased 1,784 shares of the firm’s stock in a transaction on Monday, December 22nd. The stock was bought at an average cost of $84.06 per share, with a total value of $149,963.04. Following the completion of the acquisition, the director directly owned 9,445 shares of the company’s stock, valued at $793,946.70. This trade represents a 23.29% increase in their position. The SEC filing for this purchase provides additional information. In the last ninety days, insiders purchased 16,014 shares of company stock worth $1,304,416. Insiders own 1.98% of the company’s stock.

Institutional Trading of Cooper Companies

Several institutional investors have recently modified their holdings of the stock. Cresset Asset Management LLC raised its position in shares of Cooper Companies by 7.5% during the 3rd quarter. Cresset Asset Management LLC now owns 4,393 shares of the medical device company’s stock worth $301,000 after purchasing an additional 306 shares during the last quarter. Captrust Financial Advisors increased its stake in Cooper Companies by 10.0% during the 2nd quarter. Captrust Financial Advisors now owns 3,500 shares of the medical device company’s stock worth $249,000 after buying an additional 317 shares in the last quarter. Snowden Capital Advisors LLC raised its holdings in shares of Cooper Companies by 10.0% during the second quarter. Snowden Capital Advisors LLC now owns 4,088 shares of the medical device company’s stock valued at $291,000 after acquiring an additional 373 shares during the last quarter. Public Employees Retirement System of Ohio boosted its stake in Cooper Companies by 0.6% during the 3rd quarter. Public Employees Retirement System of Ohio now owns 62,229 shares of the medical device company’s stock worth $4,266,000 after purchasing an additional 386 shares during the last quarter. Finally, Arkadios Wealth Advisors grew its stake in Cooper Companies by 14.3% during the 4th quarter. Arkadios Wealth Advisors now owns 3,552 shares of the medical device company’s stock valued at $291,000 after acquiring an additional 444 shares in the last quarter. Institutional investors and hedge funds own 24.39% of the company’s stock.

About Cooper Companies

Cooper Companies, Inc (NASDAQ: COO) is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company has grown through strategic acquisitions and organic development to become a major provider of vision care and women’s health products. Cooper Companies operates through two primary business segments—CooperVision and CooperSurgical—each serving specialized markets within the healthcare industry.

The CooperVision segment develops, manufactures and markets a broad range of soft contact lenses, as well as related accessories.